 Piracetam
"Piracetam" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A compound suggested to be both a nootropic and a neuroprotective agent.
| Descriptor ID |
D010889
|
| MeSH Number(s) |
D02.065.064.650 D02.241.081.018.110.650 D03.383.773.812.555
|
| Concept/Terms |
Piracetam- Piracetam
- Pyramem
- Pyracetam
- 2-Pyrrolidone-N-Acetamide
- Pirazetam
Axonyl- Axonyl
- Pfizer Brand of Piracetam
Dinagen- Dinagen
- Hormona Brand of Piracetam
Gabacet- Gabacet
- Sanofi Synthelabo Brand of Piracetam
Geram- Geram
- Vedim Brand of Piracetam
Memo-Puren- Memo-Puren
- Memo Puren
- Alpharma Brand of Piracetam
Nootropil- Nootropil
- UCB Brand of Piracetam
- Normabraïn
- Nootrop
- Nootropyl
Sinapsan- Sinapsan
- Rodleben Brand of Piracetam
- Piracetam-RPh
- Piracetam RPh
Avigilen- Avigilen
- Riemser Brand of Piracetam
|
Below are MeSH descriptors whose meaning is more general than "Piracetam".
Below are MeSH descriptors whose meaning is more specific than "Piracetam".
This graph shows the total number of publications written about "Piracetam" by people in this website by year, and whether "Piracetam" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 3 | 4 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 2 | 1 | 3 | | 2009 | 1 | 0 | 1 | | 2013 | 0 | 2 | 2 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Piracetam" by people in Profiles.
-
DeMott JM, Slocum GW, Gottlieb M, Peksa GD. Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis. Epilepsy Behav. 2020 10; 111:107286.
-
Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, Fountain N, Jones E, Lowenstein D, Shinnar S, Silbergleit R, Treiman D, Trinka E, Kapur J. The established status epilepticus trial 2013. Epilepsia. 2013 Sep; 54 Suppl 6:89-92.
-
Riviello JJ, Claassen J, LaRoche SM, Sperling MR, Alldredge B, Bleck TP, Glauser T, Shutter L, Treiman DM, Vespa PM, Bell R, Brophy GM. Treatment of status epilepticus: an international survey of experts. Neurocrit Care. 2013 Apr; 18(2):193-200.
-
Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, Lydiard RB, Pollack MH. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010 May; 71(5):627-31.
-
Pollack MH, Jensen JE, Simon NM, Kaufman RE, Renshaw PF. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 01; 32(3):739-43.
-
Kinrys G, Worthington JJ, Wygant L, Nery F, Reese H, Pollack MH. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry. 2007 Jul; 68(7):1010-3.
-
Bleck TP. Intensive care unit management of patients with status epilepticus. Epilepsia. 2007; 48 Suppl 8:59-60.
-
Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou E, Soorya L, Hollander E. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 2006 Nov; 21(6):363-7.
-
Richards KC, Smith MC, Verma A. Continued use of zonisamide following development of renal calculi. Neurology. 2005 Feb 22; 64(4):763-4.
-
Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, Link N, Pollack MH. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004 Sep; 65(9):1219-22.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|